Guide Therapeutics
United States
acquired
acquired
Stage
1
Investors
About
Develops and identifies lipid nanoparticles for targeted delivery of genetic medicines using DNA barcoding to screen and discover nanoparticles that efficiently deliver nucleic-acid therapies to specific tissues and organs.
Explore Guide Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.